Clinicopathological evaluation of renal allograft treated with anti-CD25 monoclonal antibody.
Twenty-seven living-donor kidney recipients were treated with the antibody against CD25 as the induction immunosuppressive agent. They did not develop acute rejection within 1 month after transplantation, and mean serum creatinine level at 1 month was 1.0 +/- 0.4 mg/dL. There were no findings of acute rejection or drug-induced nephrotoxicity in protocol biopsies at 1 month following transplantation. After 1 month had passed, acute rejection occurred in three cases. The pathological grade of acute rejection varied from borderline to grade III by Banff classification. The careful inspection is necessary to find out the occurrences of acute rejection more than 2 months after transplantation because immunological situation has been changing around this period.
Okamoto
Masahiko
M
Department of Organ interaction Research Medicine, Kyoto Prefectural University of Medicine, Kyoto, Japan. amoto@koto.kpu-m.ac.jp
Akioka
Kiyokazu
K
Higuchi
Atsushi
A
Kadotani
Yayoi
Y
Ushigome
Hidetaka
H
Uryuhara
Kenji
K
Kaihara
Satoshi
S
Yoshimura
Norio
N
D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000077552:Basiliximab; D002648:Child; D005260:Female; D005500:Follow-Up Studies; D006084:Graft Rejection / Q000473:pathology* / Q000517:prevention & control*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D016030:Kidney Transplantation / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D015375:Receptors, Interleukin-2 / Q000037:antagonists & inhibitors*; D011993:Recombinant Fusion Proteins / Q000627:therapeutic use*; D012189:Retrospective Studies; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D007166:Immunosuppressive Agents; D015375:Receptors, Interleukin-2; D011993:Recombinant Fusion Proteins; D000077552:Basiliximab